Legend to double Carvykti production as it targets blockbuster status news2025-03-12T11:19:37+00:00March 12th, 2025|Endpoints News|
Bristol Myers buys out cell therapy partner 2seventy bionews2025-03-11T07:13:39+00:00March 11th, 2025|Endpoints News|
Beam shares promising first clinical data on gene editing treatmentnews2025-03-10T15:42:30+00:00March 10th, 2025|Endpoints News|
How bluebird’s buyout offer went from $100M upfront to $29Mnews2025-03-07T18:25:38+00:00March 7th, 2025|Endpoints News|
Luxa’s stem cell therapy for dry AMD shows early promisenews2025-03-06T15:30:04+00:00March 6th, 2025|Endpoints News|
Regeneron, two Chinese biotechs tout promise of their hearing loss gene therapiesnews2025-02-26T16:30:13+00:00February 26th, 2025|Endpoints News|
Deerfield sues Alcon over alleged scheme to obstruct Aurion’s IPOnews2025-02-24T21:02:34+00:00February 24th, 2025|Endpoints News|
Bluebird bio to sell to investment funds after struggling to make money from gene therapiesnews2025-02-21T16:34:08+00:00February 21st, 2025|Endpoints News|
Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy fieldnews2025-02-21T12:24:53+00:00February 21st, 2025|Endpoints News|
Biotech is still trying to make CRISPR a successnews2025-02-19T15:00:35+00:00February 19th, 2025|Endpoints News|
